Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.574 CHF
−11.51 M CHF
159.44 M CHF
144.70 M
About Valneva SE
Sector
Industry
CEO
Thomas Lingelbach
Website
Headquarters
Saint-Herblain
Founded
1999
ISIN
FR0004056851
FIGI
BBG007FJNFR8
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
00897
Fubon NYSE Factset Global Genomics and Immuno Biopharma ETFWeight
1.16%
Market value
599.39 K
USD
XDNA
iShares Genomics Immunology and Healthcare Index ETF Trust UnitsWeight
1.19%
Market value
47.37 K
USD
EMUSC.EUR
UBS (Lux) Fund Solutions SICAV - UBS MSCI EMU Small Cap UCITS ETF EUR acc- CapitalisationWeight
0.01%
Market value
40.24 K
USD
EMUSCD.EUR
UBS (Lux) Fund Solutions SICAV - UBS MSCI EMU Small Cap UCITS ETF EUR Ukdis- DistributionWeight
0.01%
Market value
40.24 K
USD
UEFD
UBS (Lux) Fund Solutions SICAV - UBS MSCI EMU Small Cap UCITS ETF EUR dis- DistributionWeight
0.01%
Market value
40.24 K
USD
INDEP
Multi Units Luxembourg SICAV - AMUNDI European Strategic Autonomy -UCITS ETF- CapitalisationWeight
0.01%
Market value
247.70
USD
Explore more ETFs
Frequently Asked Questions
The current price of VLA is 3.632 CHF — it has increased by 3.42% in the past 24 hours. Watch Valneva SE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Valneva SE stocks are traded under the ticker VLA.
VLA stock has risen by 3.24% compared to the previous week, the month change is a −12.25% fall, over the last year Valneva SE has showed a 8.84% increase.
We've gathered analysts' opinions on Valneva SE future price: according to them, VLA price has a max estimate of 9.29 CHF and a min estimate of 3.25 CHF. Watch VLA chart and read a more detailed Valneva SE stock forecast: see what analysts think of Valneva SE and suggest that you do with its stocks.
VLA stock is 3.58% volatile and has beta coefficient of 2.23. Track Valneva SE stock price on the chart and check out the list of the most volatile stocks — is Valneva SE there?
Today Valneva SE has the market capitalization of 603.04 M, it has increased by 2.48% over the last week.
Yes, you can track Valneva SE financials in yearly and quarterly reports right on TradingView.
Valneva SE is going to release the next earnings report on Mar 19, 2026. Keep track of upcoming events with our Earnings Calendar.
VLA earnings for the last quarter are −0.20 CHF per share, whereas the estimation was −0.14 CHF resulting in a −40.73% surprise. The estimated earnings for the next quarter are −0.14 CHF per share. See more details about Valneva SE earnings.
Valneva SE revenue for the last quarter amounts to 18.73 M CHF, despite the estimated figure of 30.08 M CHF. In the next quarter, revenue is expected to reach 42.08 M CHF.
VLA net income for the last quarter is −41.46 M CHF, while the quarter before that showed −10.83 M CHF of net income which accounts for −282.84% change. Track more Valneva SE financial stats to get the full picture.
No, VLA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2025, the company has 713 employees. See our rating of the largest employees — is Valneva SE on this list?
Like other stocks, VLA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Valneva SE stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Valneva SE technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Valneva SE stock shows the strong buy signal. See more of Valneva SE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.